Latest Insider Transactions at Applied Molecular Transport Inc. (AMTI)
This section provides a real-time view of insider transactions for Applied Molecular Transport Inc. (AMTI). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Applied Molecular Transport Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Applied Molecular Transport Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 01
2022
|
Bittoo Kanwar Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,792
-2.12%
|
$3,584
$2.97 P/Share
|
|
Jun 01
2022
|
Tahir Ph.D. Mahmood Director |
SELL
Open market or private sale
|
Direct |
1,382
-1.77%
|
$2,764
$2.97 P/Share
|
|
Jun 01
2022
|
Randall Ph.D. Mrsny Director |
SELL
Open market or private sale
|
Direct |
319
-1.54%
|
$638
$2.97 P/Share
|
|
Jun 01
2022
|
Douglas A. Rich Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
2,123
-3.59%
|
$4,246
$2.97 P/Share
|
|
May 23
2022
|
David Lamond Director |
BUY
Open market or private purchase
|
Indirect |
33,500
+3.02%
|
$100,500
$3.26 P/Share
|
|
May 20
2022
|
David Lamond Director |
BUY
Open market or private purchase
|
Indirect |
33,000
+3.06%
|
$99,000
$3.08 P/Share
|
|
May 16
2022
|
Shawn Cross CEO & Chair of the Board |
BUY
Grant, award, or other acquisition
|
Direct |
18,000
+20.51%
|
-
|
|
May 16
2022
|
Brandon Hants CFO |
BUY
Grant, award, or other acquisition
|
Direct |
7,500
+17.52%
|
-
|
|
May 13
2022
|
Epiq Capital Group, LLC |
BUY
Open market or private purchase
|
Indirect |
29,763
+0.36%
|
$119,052
$4.17 P/Share
|
|
May 12
2022
|
Epiq Capital Group, LLC |
BUY
Open market or private purchase
|
Indirect |
32,380
+0.39%
|
$97,140
$3.88 P/Share
|
|
Mar 01
2022
|
Aaron Van Devender Director |
BUY
Open market or private purchase
|
Direct |
45,888
+42.27%
|
$275,328
$6.34 P/Share
|
|
Feb 28
2022
|
Aaron Van Devender Director |
BUY
Open market or private purchase
|
Direct |
4,112
+19.69%
|
$24,672
$6.51 P/Share
|
|
Feb 15
2022
|
Elizabeth Bhatt Chief Bus. & Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,250
+26.14%
|
-
|
|
Feb 15
2022
|
Shawn Cross CEO & Chair of the Board |
BUY
Grant, award, or other acquisition
|
Direct |
20,250
+28.13%
|
-
|
|
Feb 15
2022
|
Brandon Hants CFO |
BUY
Grant, award, or other acquisition
|
Direct |
12,300
+30.67%
|
-
|
|
Feb 15
2022
|
Bittoo Kanwar Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,600
+20.34%
|
-
|
|
Feb 15
2022
|
Tahir Ph.D. Mahmood Director |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+49.02%
|
-
|
|
Feb 15
2022
|
Randall Ph.D. Mrsny Director |
BUY
Grant, award, or other acquisition
|
Direct |
17,250
+45.39%
|
-
|
|
Feb 15
2022
|
Douglas A. Rich Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,200
+24.49%
|
-
|
|
Jan 28
2022
|
Tahir Ph.D. Mahmood Director |
BUY
Open market or private purchase
|
Direct |
3,000
+50.0%
|
$21,000
$7.88 P/Share
|
|
Dec 24
2021
|
Elizabeth Bhatt Chief Bus. & Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
31,500
+50.0%
|
-
|
|
Dec 24
2021
|
Shawn Cross CEO & Chair of the Board |
BUY
Grant, award, or other acquisition
|
Direct |
31,500
+50.0%
|
-
|
|
Dec 24
2021
|
Brandon Hants CFO |
BUY
Grant, award, or other acquisition
|
Direct |
15,500
+50.0%
|
-
|
|
Dec 24
2021
|
Bittoo Kanwar Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
31,500
+33.33%
|
-
|
|
Dec 24
2021
|
Douglas A. Rich Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+50.0%
|
-
|
|
Dec 22
2021
|
Bittoo Kanwar Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
31,500
+50.0%
|
$63,000
$2.38 P/Share
|
|
Dec 09
2021
|
Randall Ph.D. Mrsny Director |
BUY
Open market or private purchase
|
Direct |
3,500
+50.0%
|
$49,000
$14.99 P/Share
|
|
Nov 17
2021
|
Epiq Capital Group, LLC |
BUY
Open market or private purchase
|
Indirect |
7,135
+0.09%
|
$156,970
$22.38 P/Share
|
|
Nov 16
2021
|
Epiq Capital Group, LLC |
BUY
Open market or private purchase
|
Indirect |
4,000
+0.05%
|
$88,000
$22.57 P/Share
|
|
Aug 27
2021
|
Helen Susan Kim Director |
SELL
Open market or private sale
|
Direct |
951
-0.08%
|
$29,481
$31.1 P/Share
|
|
Aug 26
2021
|
Helen Susan Kim Director |
SELL
Open market or private sale
|
Direct |
14,063
-1.19%
|
$421,890
$30.57 P/Share
|
|
Aug 25
2021
|
Helen Susan Kim Director |
SELL
Open market or private sale
|
Direct |
9,478
-1.58%
|
$284,340
$30.08 P/Share
|
|
Aug 24
2021
|
Helen Susan Kim Director |
SELL
Open market or private sale
|
Direct |
508
-0.04%
|
$15,240
$30.04 P/Share
|
|
Aug 23
2021
|
Shawn Cross CEO & Chair of the Board |
SELL
Open market or private sale
|
Direct |
9,700
-100.0%
|
$291,000
$30.12 P/Share
|
|
Aug 23
2021
|
Shawn Cross CEO & Chair of the Board |
BUY
Exercise of conversion of derivative security
|
Direct |
9,700
+50.0%
|
$38,800
$4.61 P/Share
|
|
Aug 19
2021
|
Shawn Cross CEO & Chair of the Board |
SELL
Open market or private sale
|
Direct |
300
-100.0%
|
$9,000
$30.01 P/Share
|
|
Aug 19
2021
|
Shawn Cross CEO & Chair of the Board |
BUY
Exercise of conversion of derivative security
|
Direct |
300
+50.0%
|
$1,200
$4.61 P/Share
|
|
Jul 21
2021
|
Elizabeth Bhatt Chief Bus. & Strategy Officer |
SELL
Open market or private sale
|
Direct |
9,000
-86.89%
|
$324,000
$36.92 P/Share
|
|
Jul 21
2021
|
Elizabeth Bhatt Chief Bus. & Strategy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,000
+50.0%
|
$36,000
$4.61 P/Share
|
|
Jul 07
2021
|
Bittoo Kanwar Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,500
-94.3%
|
$315,000
$42.84 P/Share
|
|
Jul 07
2021
|
Bittoo Kanwar Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+50.0%
|
$15,000
$2.38 P/Share
|
|
Jul 02
2021
|
Helen Susan Kim Director |
SELL
Open market or private sale
|
Direct |
200,000
-12.53%
|
$8,800,000
$44.81 P/Share
|
|
Apr 21
2021
|
Elizabeth Bhatt Chief Bus. & Strategy Officer |
SELL
Open market or private sale
|
Direct |
9,000
-59.42%
|
$360,000
$40.3 P/Share
|
|
Apr 21
2021
|
Elizabeth Bhatt Chief Bus. & Strategy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,000
+50.0%
|
$36,000
$4.61 P/Share
|
|
Apr 07
2021
|
Bittoo Kanwar Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,500
-58.13%
|
$412,500
$55.03 P/Share
|
|
Apr 07
2021
|
Bittoo Kanwar Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+50.0%
|
$15,000
$2.38 P/Share
|
|
Apr 06
2021
|
David Lamond Director |
BUY
Open market or private purchase
|
Indirect |
25,000
+2.41%
|
$1,050,000
$42.0 P/Share
|
|
Jun 09
2020
|
Epiq Capital Group, LLC |
BUY
Open market or private purchase
|
Indirect |
2,720,000
+13.15%
|
$38,080,000
$14.0 P/Share
|
|
Jun 09
2020
|
Epiq Capital Group, LLC |
BUY
Conversion of derivative security
|
Indirect |
5,544,240
+43.99%
|
-
|